ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study

Huang, Jian; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Li, Xiane; Liu, Gaijiao; Hu, Hao*; Huang, Shaohong*; Yang, Xiongwen*广东医学院; 深圳市第二人民医院; 中山大学
BMC CANCER2023-8-30DOI: 10.1186/s12885-023-11312-4
1被引7阅读
引用收藏
分享

摘要

Background This study aimed to investigate the association between baseline serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate antigen 19-9 [CA19-9], and carbohydrate antigen 125 [CA125]) and the efficacy of first-line immunotherapy in patients with advanced non-small cell lung cancer.Methods This multicenter retrospective study evaluated patients who received first-line immunotherapy between July 2017 and July 2022. The endpoints were progression-free survival (PFS) and overall survival (OS), as defined by the Response Evaluation Criteria in Solid Tumors version 1.1. We divided the patients into three groups based on STM levels: Group A =threefold upper limit of normal, threefold upper limit of normal > Group B > upper limit of normal, and Group C =upper limit of normal.Results In total, 716 patients were included in this study. In Cox proportional hazards analyses, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung adenocarcinoma (LUAD). Except for CA19-9 level, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung squamous carcinoma (LUSC). Except for CEA and CA19-9 levels, the levels in Group A were independently associated with inferior PFS and OS in patients with LUAD and LUSC.Conclusions Serum CEA, NSE, CYFRA21-1, and CA125 levels can predict PFS and OS in patients with LUAD and LUSC, and serum CA19-9 levels can predict PFS and OS in patients with LUAD. The higher the serum NSE, CYFRA21-1, and CA125 levels, the worse the PFS and OS in patients with LUAD and LUSC. In addition, the higher the serum CA19-9 level, the worse the OS in patients with LUAD.

学科与关键词

关键词
Non-small cell lung cancerBaseline serum tumor markersImmunotherapyProgression-free survivalOverall survival
相关
加载中…
  • Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study
    Yang, Xiongwen; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Hu, Hao*; Huang, Jian*; Huang, Shaohong*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231206282.
  • Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study
    Liu, Shuai; Zhao, Liuyuan; Zhou, Guohua*Frontiers in Genetics, 2022, 13: 1016085.被引 1
  • Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study
    Zheng, Xinlong; Zhang, Longfeng; Wu, Lin; Zhao, Jun; Sun, Jianguo; Fang, Yong; Zhou, Jin; Chu, Qian; Shen, Yihong; Yang, Zhenzhou; Chen, Lijin; Huang, Meijuan; Lin, Xiaoyan; Liu, Zhenhua; Shen, Peng; Wang, Zhijie; Wang, Xin; Wang, Huijuan; Han, Zhengbo; Liu, Anwen; Zhang, Hongmei; Ye, Feng; Gao, Wen; Wu, Fang; Song, Zhengbo; Chen, Shengchi; Zhou, Chenzhi; Wang, Qian; Xu, Chunwei; Huang, Dingzhi; Zheng, Xiaobin; Miao, Qian; Jiang, Kan; Xu, Yiquan; Wu, Shiwen; Wang, Haibo; Zhang, QiuyuBMC CANCER, 2023, 23(1): 1244.
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2023-08-30
卷期
第 23 卷, 第 1 期
页码
812
DOI
10.1186/s12885-023-11312-4
语言
ENGLISH
成果收录
SCIE
资助标注
Medical Scientific Research Foundation of Guangdong Province, China [A2022142]

作者

  • H

    Huang, Jian (第一作者)

    jiangxi canc hosp

  • X

    Xiao, Yi

    sun yat sen univ

查看全部 12 位作者收起作者
  • Z

    Zhou, Yubin

    sun yat sen univ

  • D

    Deng, Huiyin

  • Y

    Yuan, Zihao

    2 · guangdong med univ

  • D

    Dong, Longyan

    2 · guangdong med univ

  • L

    Lan, Jun

  • L

    Li, Xiane

    jiangxi canc hosp

  • L

    Liu, Gaijiao

    shenzhen second peoples hosp

  • H

    Hu, Hao (通讯)

  • H

    Huang, Shaohong (通讯)

    sun yat sen univ

  • Y

    Yang, Xiongwen (通讯)

    jiangxi canc hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417